Cedric Hermans/LinkedIn
Aug 13, 2025, 23:32
Cedric Hermans Shares His Vision for the Use of APCC During Emicizumab Prophylaxis
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, recently shared on LinkedIn:
”Personal commentary on the recent important paper by Robert Sidonio et al. on APCC in patients receiving emicizumab prophylaxis published in RPTH.”
Read the full article here.
Article: Cautious use of activated prothrombin complex concentrate in patients receiving emicizumab: new evidence and clinical considerations
Author: Cedric Hermans
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Sep 4, 2026, 18:49Børge Nordestgaard: Lp(a) Remains a Risk Factor Across the Lifespan
-
Sep 4, 2026, 18:22Tareq Abadl: The Clinical Meaning of C3 and C4
-
Sep 4, 2026, 18:16How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
-
Sep 4, 2026, 18:08Simon Kraler: Can the Adrenomedullin System Predict Cardiogenic Shock Before It Happens?
-
Sep 4, 2026, 17:56Maxime Dely: Why Every Blood Donation Matters
-
Sep 4, 2026, 17:28Shinya Goto: When Cardiovascular Risk Gets Lower, RCTs Get Harder
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action